However, in a real-world situation, the reduction of tumor size cannot exceed 100%, which means that patients with positive AFP both before initiation of systemic therapy and surgery (i.e., AFP response = 0) are more unlikely to achieve a pCR. This evidence concerns the gene AFP and neoplasm.